OncoMatch/Clinical Trials/CNS Lymphoma (PCNSL)
CNS Lymphoma (PCNSL) Clinical Trials
OncoMatch filters CNS Lymphoma (PCNSL) trials by the molecular markers that determine eligibility — MYD88, CD79B, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaAbout CNS Lymphoma (PCNSL) trials
Primary CNS lymphoma (PCNSL) is a rare, aggressive lymphoma confined to the central nervous system. MYD88 L265P and CD79B mutations together characterize the activated B-cell-like (ABC) DLBCL subtype that dominates PCNSL, with both mutations driving BTK pathway activation. This molecular dependency underlies the activity of BTK inhibitors in PCNSL.
Trial selection in PCNSL depends on disease state and prior high-dose methotrexate (HD-MTX) exposure. Front-line trials test variations on HD-MTX-based induction (R-MPV, MATRix-style regimens) and consolidation strategies (autologous stem cell transplant vs whole brain radiation, with autoSCT increasingly preferred to spare neurocognitive function). R/R trials test BTK inhibitors (which exploit the MYD88 / CD79B-driven BTK dependency), immunomodulatory drugs (lenalidomide), and novel combinations including bispecific antibodies. Elderly PCNSL trials (often patients >70) test de-intensified HD-MTX or non-MTX regimens for patients who can't tolerate full-dose induction.
PCNSL trial screening typically checks performance status, prior HD-MTX, and renal function. Performance status, often by Karnofsky for CNS-related fitness assessment, is foundational. Prior HD-MTX exposure (and number of cycles) defines whether front-line or post-induction trials apply. Prior autologous stem cell transplant status for consolidation or salvage trials. Prior BTK inhibitor exposure for R/R trials. Renal function (creatinine clearance) is screened on most trials because HD-MTX requires intact renal clearance. HIV status and immune competence for HIV-associated PCNSL trials.
Top recruiting CNS Lymphoma (PCNSL) trials
Ranked by phase and number of US sites. See all trials matched to your profile →
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine GmbH
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Dana-Farber Cancer Institute
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Estrella Biopharma, Inc.
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Medical College of Wisconsin
How OncoMatch finds CNS Lymphoma (PCNSL) trials for you
AI reads the protocol
Every CNS Lymphoma (PCNSL) trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select CNS Lymphoma (PCNSL) and mark your biomarker results — MYD88, CD79B — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.